Amgen, Inc.

Amgen has filed a second federal lawsuit against Colorado's Prescription Drug Affordability Board, challenging the state's first-in-the-nation price ceiling on arthritis drug Enbrel set at $31,000 per year.

TScan Therapeutics reached alignment with the FDA on a pivotal study design for TSC-101 to treat acute myeloid leukemia and myelodysplastic syndromes, with the trial expected to begin in Q2 2026.

Endo has launched the first and only FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) oral liquid in the United States, providing a new treatment option for patients with urea cycle disorders.

Over 35 CD40-targeted therapies are currently in clinical trials, with the first approval expected by 2027 according to new market research.

AI Technology Group has signed a definitive agreement to acquire AVM Biotechnology, developer of the investigational cancer drug AVM0703, which reactivates the body's reserve immune system through a simple one-hour outpatient infusion.

Arthrosi Therapeutics completed a $153 million Series E funding round led by Prime Eight Capital to advance pozdeutinurad (AR882) through Phase III trials for gout treatment.

Amgen launched AmgenNow, a direct-to-patient program offering Repatha at $239 per month, nearly 60% below the current U.S. list price.

Colorado's Prescription Drug Affordability Board voted to establish a $600 per unit price ceiling for Enbrel, marking the first state-level drug price limit in the United States.

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

Amgen's Phase 3 VESALIUS-CV trial demonstrated that Repatha significantly reduced major adverse cardiovascular events in over 12,000 high-risk patients without prior heart attack or stroke history.